SANDOZ OSELTAMIVIR DIN 02504022
Status: Marketed
Holder: SANDOZ CANADA INCORPORATED
Molecule: OSELTAMIVIR (OSELTAMIVIR PHOSPHATE)
Available to quote
Health Canada record
| Active ingredient(s) | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 75 MG |
|---|---|
| Dosage form | Capsule |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J05AH02 OSELTAMIVIR |
| Original market date | 02-Oct-2020 |
| Current status date | 15-Apr-2025 |
| Source | Health Canada DPD |
Establishment licence of the holder
Sandoz Canada Incorporated — licence 101370, currently licensed, last inspection rating C (2025-02-25).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing OSELTAMIVIR (OSELTAMIVIR PHOSPHATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02536919 | ACH-OSELTAMIVIR PHOSPHATE | ACCORD HEALTHCARE INC | Capsule | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 75 MG | Approved |
| 02536900 | ACH-OSELTAMIVIR PHOSPHATE | ACCORD HEALTHCARE INC | Capsule | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 45 MG | Approved |
| 02536897 | ACH-OSELTAMIVIR PHOSPHATE | ACCORD HEALTHCARE INC | Capsule | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 30 MG | Approved |
| 02510251 | AG-OSELTAMIVIR | ANGITA PHARMA INC. | Capsule | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 30 MG | Approved |
| 02510286 | AG-OSELTAMIVIR | ANGITA PHARMA INC. | Capsule | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 75 MG | Approved |
| 02510278 | AG-OSELTAMIVIR | ANGITA PHARMA INC. | Capsule | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 45 MG | Approved |
| 02497417 | JAMP OSELTAMIVIR | JAMP PHARMA CORPORATION | Capsule | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 45 MG | Approved |
| 02497409 | JAMP OSELTAMIVIR | JAMP PHARMA CORPORATION | Capsule | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 30 MG | Marketed |
| 02497425 | JAMP OSELTAMIVIR | JAMP PHARMA CORPORATION | Capsule | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 75 MG | Marketed |
| 02497441 | MINT-OSELTAMIVIR | MINT PHARMACEUTICALS INC | Capsule | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 30 MG | Marketed |
| 02497476 | MINT-OSELTAMIVIR | MINT PHARMACEUTICALS INC | Capsule | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 75 MG | Marketed |
| 02497468 | MINT-OSELTAMIVIR | MINT PHARMACEUTICALS INC | Capsule | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 45 MG | Approved |
| 02457989 | NAT-OSELTAMIVIR | NATCO PHARMA (CANADA) INC | Capsule | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 75 MG | Marketed |
| 02472643 | NAT-OSELTAMIVIR | NATCO PHARMA (CANADA) INC | Capsule | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 45 MG | Marketed |
| 02499894 | NAT-OSELTAMIVIR | NATCO PHARMA (CANADA) INC | Powder For Suspension | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 6 MG | Marketed |
| 02472635 | NAT-OSELTAMIVIR | NATCO PHARMA (CANADA) INC | Capsule | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 30 MG | Marketed |
| 02509962 | OSELTAMIVIR POWDER FOR ORAL SUSPENSION | STRIDES PHARMA CANADA INC | Powder For Suspension | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 6 MG | Approved |
| 02504006 | SANDOZ OSELTAMIVIR | SANDOZ CANADA INCORPORATED | Capsule | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 30 MG | Marketed |
| 02504014 | SANDOZ OSELTAMIVIR | SANDOZ CANADA INCORPORATED | Capsule | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 45 MG | Marketed |
| 02241472 | TAMIFLU | HOFFMANN-LA ROCHE LIMITED | Capsule | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 75 MG | Marketed |
| 02381842 | TAMIFLU | HOFFMANN-LA ROCHE LIMITED | Powder For Suspension | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 6 MG | Marketed |
| 02304856 | TAMIFLU | HOFFMANN-LA ROCHE LIMITED | Capsule | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 45 MG | Marketed |
| 02304848 | TAMIFLU | HOFFMANN-LA ROCHE LIMITED | Capsule | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 30 MG | Marketed |
| 02497379 | MAR-OSELTAMIVIR | MARCAN PHARMACEUTICALS INC | Capsule | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 75 MG | Cancelled Post Market |
| 02497360 | MAR-OSELTAMIVIR | MARCAN PHARMACEUTICALS INC | Capsule | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 45 MG | Cancelled Post Market |
| 02497352 | MAR-OSELTAMIVIR | MARCAN PHARMACEUTICALS INC | Capsule | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 30 MG | Cancelled Post Market |
| 02478412 | MYLAN-OSELTAMIVIR | MYLAN PHARMACEUTICALS ULC | Capsule | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 30 MG | Cancelled Pre Market |
| 02478439 | MYLAN-OSELTAMIVIR | MYLAN PHARMACEUTICALS ULC | Capsule | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 75 MG | Cancelled Pre Market |
| 02478420 | MYLAN-OSELTAMIVIR | MYLAN PHARMACEUTICALS ULC | Capsule | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 45 MG | Cancelled Pre Market |
| 02245549 | TAMIFLU ORAL SUSPENSION | HOFFMANN-LA ROCHE LIMITED | Powder For Suspension | OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 12 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 34007 | 2024-09-09 | Abbreviated New Drug Submission (ANDS) | Administrative: Change in product ownership |
| 24118 | 2020-08-24 | Abbreviated New Drug Submission (ANDS) |